XML 52 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment and Geographic Area Information Segment and Geographic Area Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.
Medical Devices—Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers (a)Operating Earnings (a)
(in millions)202220212020202220212020
Established Pharmaceutical Products$4,912 $4,718 $4,303 $1,049 $889 $794 
Nutritional Products7,459 8,294 7,647 706 1,763 1,751 
Diagnostic Products16,584 15,644 10,805 6,667 6,256 3,725 
Medical Devices14,687 14,367 11,787 4,409 4,514 3,038 
Total Reportable Segments43,642 43,023 34,542 $12,831 $13,422 $9,308 
Other11 52 66 
Total$43,653 $43,075 $34,608 
________________________________________________________
(a)
In 2022 and 2020, the impact of foreign exchange unfavorably impacted net sales and operating earnings. In 2021, the impact of foreign exchange favorably impacted net sales and unfavorably impacted operating earnings.
(in millions)202220212020
Total Reportable Segment Operating Earnings$12,831 $13,422 $9,308 
Corporate functions and benefit plan costs(509)(801)(518)
Net interest expense(375)(490)(500)
Share-based compensation(685)(640)(546)
Amortization of intangible assets(2,013)(2,047)(2,132)
Other, net (b)(943)(1,233)(644)
Earnings from Continuing Operations Before Taxes$8,306 $8,211 $4,968 
________________________________________________________
(b)
Other, net in 2022 includes $176 million of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net also includes integration costs associated with the acquisitions of Alere Inc. and St. Jude Medical and restructuring charges in 2022, 2021 and 2020. Charges for restructuring actions and other cost reduction initiatives were approximately $265 million in 2022, $375 million in 2021 and $125 million in 2020. Other, net in 2021 also includes costs related to certain litigation. Other, net in 2020 also includes costs related to asset impairments partially offset by income from the settlement of litigation.

DepreciationAdditions to
Property and Equipment		Total Assets
(in millions)202220212020202220212020202220212020
Established Pharmaceuticals$97 $94 $88 $175 $169 $109 $2,883 $2,789 $2,888 
Nutritionals155 151 143 251 174 201 3,625 3,425 3,478 
Diagnostics494 760 488 832 980 1,263 7,985 7,699 7,696 
Medical Devices311 285 281 335 348 402 7,844 7,261 6,893 
Total Reportable Segments1,057 1,290 1,000 1,593 1,671 1,975 $22,337 $21,174 $20,955 
Other197 201 195 182 201 218 
Total$1,254 $1,491 $1,195 $1,775 $1,872 $2,193 
(in millions)20222021
Total Reportable Segment Assets$22,337 $21,174 
Cash and investments10,936 11,065 
Goodwill and intangible assets33,253 35,970 
All other (c)7,912 6,987 
Total Assets$74,438 $75,196 
________________________________________________________
(c)
All other includes the long-term assets associated with the defined benefit plans of $3.20 billion in 2022 and $2.27 billion in 2021.
Net Sales to External
Customers (d)
(in millions)202220212020
United States$18,142 $16,642 $13,022 
Germany2,340 2,572 2,108 
China2,133 2,392 1,965 
Japan1,932 1,695 1,386 
India1,649 1,561 1,323 
Switzerland1,336 1,313 1,140 
Canada1,280 1,385 841 
All Other Countries14,841 15,515 12,823 
Consolidated$43,653 $43,075 $34,608 
________________________________________________________
(d)Sales by country are based on the country that sold the product.
Long-lived assets on a geographic basis primarily include property and equipment. It excludes goodwill, intangible assets, deferred tax assets, and financial instruments. At December 31, 2022 and 2021, long-lived assets totaled $14.2 billion and $13.1 billion, respectively, and in the United States such assets totaled $7.7 billion and $6.8 billion, respectively. Long-lived asset balances associated with other countries were not material on an individual country basis in either of the two years.